Memphasys Extends Convertible Note Maturity to June 2026, Retains Terms
Memphasys Limited has extended the repayment terms of its convertible notes with major shareholder Peters Investments to mid-2026, reinforcing financial flexibility amid ongoing commercial progress.
- Convertible note maturity extended to 30 June 2026
- No change to principal amount or conversion terms
- Structured timetable agreed for accrued interest repayment
- Strong shareholder confidence from Peters Investments
- Recent CE Mark approval and new commercial agreements underpin progress
Extension of Convertible Note Terms
Memphasys Limited (ASX, MEM), an Australian reproductive biotechnology company, has announced an extension to the repayment terms of its existing convertible notes held by Peters Investments Pty Ltd, a significant long-term shareholder. The maturity date for these notes has been pushed back to 30 June 2026, providing the company with additional breathing room to manage its financial obligations without altering the principal or conversion conditions.
Financial Flexibility Amid Strategic Execution
This extension is more than a mere administrative adjustment; it signals a strategic move by Memphasys to strengthen its balance sheet flexibility as it advances its commercial and regulatory objectives. The agreement also includes a structured timetable for the repayment of accrued interest, underscoring a disciplined approach to managing debt while maintaining operational momentum.
Shareholder Confidence and Strategic Alignment
The ongoing support from Peters Investments, a shareholder with a longstanding relationship with Memphasys, reflects strong confidence in the company’s current strategy and leadership. Both the Chairperson, Lindley Edwards, and Peters Investments’ Director, Robert Peters, emphasized their alignment and commitment to the company’s direction, reinforcing the positive partnership between investor and management.
Commercial Progress and Regulatory Milestones
Memphasys has recently achieved significant operational milestones, including CE Mark approval for its Felix™ System, a patented sperm selection technology, and the signing of commercial agreements with fertility clinics in Italy and India. These developments have translated into early commercial orders, positioning the company for sustained growth and broader market penetration in 2026.
Looking Ahead
With the convertible note extension in place, Memphasys is poised to continue its trajectory of strategic execution and commercialisation. The company’s focus on scaling production, improving margins, and establishing Felix™ as a global standard in assisted reproductive technology remains firmly on track, supported by both operational progress and shareholder backing.
Bottom Line?
Memphasys’ convertible note extension offers crucial financial runway as it builds on recent regulatory and commercial wins.
Questions in the middle?
- What are the detailed terms and total outstanding amount of the convertible notes?
- How will the structured interest repayment timetable impact Memphasys’ cash flow in 2026?
- What are the next commercial milestones expected following recent agreements and CE Mark approval?
